# MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia

> **NCT03008187** · PHASE1,PHASE2 · COMPLETED · sponsor: **Menarini Group** · enrollment: 73 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** MEN1703

## Key facts

- **NCT ID:** NCT03008187
- **Lead sponsor:** Menarini Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-10
- **Primary completion:** 2023-04-13
- **Final completion:** 2023-04-13
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2025-04-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03008187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03008187, "MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03008187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*